Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18295390 | 1.00 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL5151883 | 0.89 | ALOX5AP (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL5151878 | 0.89 | ALOX5AP (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL18295389 | 0.88 | ALOX5AP (0.47) | ALOX5APFEN1GPR119KDM1AKLK7 | |
| SCHEMBL18295410 | 0.88 | ALOX5AP (0.47) | ALOX5APFEN1GPR119KDM1AKLK7 | |
| SCHEMBL18616623 | 0.87 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL18616624 | 0.87 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP | |
| SCHEMBL18294083 | 0.85 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL18294082 | 0.85 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL8247133 | 0.84 | ALOX5AP (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822115-B2 | Nitrogen containing compounds and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-11-21 | — | — | US | disclosed |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NOS2, NOS1, NCF1 | CHRNB4 4785/4885CHRNA3 4842/4885CHRNB2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.